'...and C is for Clioquinol' - The AβCs of Alzheimer's disease

Trends in Neurosciences

Volumn 25, Issue 3, 2002, Pages 121-123

  Melov, Simon ^a  

^a BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; BIOLOGICAL MARKER; CLIOQUINOL; COPPER ION; FERRIC ION; METALLOPROTEIN; AMYLOID BETA PROTEIN; CHELATING AGENT; DIAGNOSTIC AGENT;

ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DEGENERATIVE DISEASE; DISEASE MARKER; DRUG ABUSE; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; HUMAN; HYDROPHOBICITY; NONHUMAN; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; ANIMAL; DISEASE MODEL; DRUG ANTAGONISM; METABOLISM; MOUSE; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SENILE PLAQUE; TRANSGENIC MOUSE;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; CHELATING AGENTS; CLIOQUINOL; DISEASE MODELS, ANIMAL; MICE; MICE, TRANSGENIC; OXIDATIVE STRESS; SENILE PLAQUES;

EID: 0036498343     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-2236(00)02086-5     Document Type: Review

References (26)

1. D. Schenk Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse Nature 400 1999 173 177
2. R.A. Cherny Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice Neuron 30 2001 665 676
3. H.L. Weiner Nasal administration of amyloid-β peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease Ann. Neurol. 48 2000 567 579
4. C. Janus Aβ-peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease Nature 408 2000 979 982
5. F. Bard Peripherally administered antibodies against amyloid β peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease Nat. Med. 6 2000 916 919
6. R.B. DeMattos Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease Proc. Natl. Acad. Sci. U. S. A. 98 2001 8850 8855
7. R.A. Cherny Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion J. Biol. Chem. 274 1999 23223 23228
8. C.S. Atwood Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis J. Biol. Chem. 273 1998 12817 12826
9. C.S. Atwood Copper catalyzed oxidation of Alzheimer A Cell. Mol. Biol. 46 2000 777 783
10. X. Huang The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction Biochemistry 38 1999 7609 7616
11. X. Huang Cu(II) potentiation of Alzheimer Aβ neurotoxicity. Correlation with cell-free hydrogen peroxide production and metal reduction J. Biol. Chem. 274 1999 37111 37116
12. M.P. Cuajungco Evidence that the β-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc J. Biol. Chem. 275 2000 19439 19442
13. A.I. Bush Rapid induction of Alzheimer Aβ amyloid formation by zinc Science 265 1994 1464 1467
14. M.A. Lovell Copper, iron and zinc in Alzheimer's disease senile plaques J. Neurol. Sci. 158 1998 47 52
15. C.C. Curtain Alzheimer's disease amyloid-β binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits J. Biol. Chem. 276 2001 20466 20473
16. A.I. Bush L.E. Goldstein Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: focus on Alzheimer's disease and age-related cataracts Novartis Found. Symp. 235 2001 26 38
17. C.A. McLean Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease Ann. Neurol. 46 1999 860 866
18. J. Wang The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging Exp. Neurol. 158 1999 328 337
19. L.F. Lue Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease Am. J. Pathol. 155 1999 853 862
20. G. Padmanabhan Clioquinol E. Klauss E. Florey Analytical Profiles of Drug Substances 1989 Academic Press 57 90
21. A.I. Bush C.L. Masters Clioquinol's return Science 292 2001 2251 2252
22. M.S. Yassin Changes in uptake of vitamin B(12) and trace metals in brains of mice treated with clioquinol J. Neurol. Sci. 173 2000 40 44
23. K. Hsiao Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice Science 274 1996 99 102
24. J.Y. Lee Histochemically reactive zinc in plaques of the Swedish mutant β-amyloid precursor protein transgenic mice J. Neurosci. 19 1999 RC10
25. M.A. Pappolla Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of Alzheimer's disease: a chronic oxidative paradigm for testing antioxidant therapies in vivo Am. J. Pathol. 152 1998 871 877
26. S.J. Haugabook Reduction of Aβ accumulation in the Tg2576 animal model of Alzheimer's disease after oral administration of the phosphatidyl-inositol kinase inhibitor wortmannin FASEB J. 15 2001 16 18